- |||||||||| RB-312 / Refuge Biotech
Journal, CAR T-Cell Therapy, PD(L)-1 Biomarker, IO biomarker: Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment. (Pubmed Central) - Mar 1, 2023
RB-312, the first clinically relevant product incorporating a CRISPRa system with non-gene editing and reversible upregulation of endogenous gene expression that promotes CAR-T cells persistence and effectiveness against HER2-expressing tumors. The autocrine effects of reversible, nanoscale IL-12 production limits the risk of off-tumor leakage and systemic toxicity.
|
